Login
EN
[EN] English [FR] Français

Explore
Statistics
Help
Start on ORBi (visitor)Start on ORBi (UMONS)MyORBi Link your ORCiD Add a new publication Generate a list of publication Improve your visibility Predatory journals Legal information Representative FAQ Should I work with this publisher?
About
What's ORBi Release notes OAI-PMH Impact and Visibility Deposit Charter
News

Back

Home
Statistics

Statistics of Inhaled cisplatin dry powder added to anti-PD1 therapy increases antitumour activity in lung cancer

Global Last 12 months Last 30 days

Contact ORBi UMONS

Administration de la valorisation de la recherche – AVRE
Place du Parc, 20
B-7000 Mons
avre@umons.ac.be
+32 (0)65 37 31 11

ORBi

Legal Information Visibility Impact and Visibility

Quick Links

Start on ORBi ORCID OAI-PMH Output

Terms of Use -Privacy Policy - ORBi UMONS is a project developed by University of Liege